Internal Lab Buildout Strategy
Pharma & Biotech
25
4
14
Voice-of-Customer Research
Due Diligence
Objective
A large pharmaceutical company engaged DeciBio to evaluate strategies for an internal build of a lab to support clinical and commercial opportunities in oncology
Our Approach
Secondary Research
- Conducted analysis of key technologies and platforms to understand potential use cases and fit for client needs in the lab build
- Evaluated the tangible and intangible value of an internal lab and trade-offs between internal build vs. outsourcing
Primary Research
- Conducted 25 telephone interviews with, lab directors, and technology KOLs to gather insights on platform / workflow requirements and evolving landscape (e.g., regulatory)
- Conducted 14 internal interviews to determine internal hypotheses, anticipated sample volumes and associated costs
Quantitative Analysis
- Built a comprehensive financial model, including CapEx / OpEx to calculate the breakeven time frame using sample volume projections
- Determined NPV under various model scenarios
Outcome
DeciBio delivered a presentation to the leadership team, key takeaways included:
- Recommendation for an internal build based on cost savings and additional intangible benefits
- Evaluation of associated risks of build
- Determined lab design configurations and built roadmap (e.g., personnel requirements, CLIA/CAP, instruments, layout etc.)
Related Client Results
Early-Stage Cancer Biomarker Testing and Treatment Landscape Assessment
Competitive Analysis
Voice-of-Customer Research
MRD Monitoring Market Assessment and Strategy
Biomarker and Diagnostics Strategy
Go-to-Market Strategy
Market Landscaping and Sizing
Cell and Gene Therapy Services Landscape Assessment
No items found.